Australia & Dane Stevens

Australia: Australia is the recipient country for Optimi Health's psilocybin capsules, providing a regulated market for the treatment of treatment-resistant depression and setting a model for psychedelic medicine use.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, expressed pride in the company's commercial supply of psilocybin and highlighted Australia's role as a model for regulated psychedelic medicine.

Australia: Australia is currently a commercial market where Optimi Health's 5mg psilocybin capsules are prescribed to patients for treatment-resistant depression, demonstrating an existing successful market for the company's products.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, highlighted the significance of the company's first shipment to the United Kingdom and its unique position as a vertically integrated GMP supplier.

Australia: Australia is a market where Optimi Health Corp.'s 5mg psilocybin formulation is already commercially prescribed for treatment-resistant depression under the country's Authorized Prescriber Scheme.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health Corp., announced the launch of the new microdose psilocybin products, highlighting their consistent dosage for controlled research.

Dane Stevens: Dane Stevens, CEO of Optimi Health, highlighted the significance of the production and export runs in expanding access to psychedelic treatments in Australia.